FCM
BTTX

Farallon Capital Management’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Farallon Capital Management’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-330,619
Closed -$357K – 182
2023
Q2 		$357K Sell
330,619
-368,423
-53% -$356K ﹤0.01% 134
2023
Q1 		$509K Sell
699,042
-114,514
-14% -$135K ﹤0.01% 149
2022
Q4 		$911K Sell
813,556
-186,444
-19% -$275K 0.01% 175
2022
Q3 		$1.76M Hold
1,000,000
– – 0.01% 208
2022
Q2 		$1.56M Sell
1,000,000
-147,400
-13% -$247K 0.01% 210
2022
Q1 		$2.27M Sell
1,147,400
-202,600
-15% -$700K 0.01% 213
2021
Q4 		$6.28M Buy
+1,350,000
New +$11.1M 0.04% 171

Other funds holding BTTX

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.37B AUM 20.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $3.03B AUM 104.56% 1-Year Est. Return